Mohit Bansal
Stock Analyst at Wells Fargo
(4.16)
# 460
Out of 5,239 analysts
205
Total ratings
64.17%
Success rate
9.17%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $250 → $265 | $227.84 | +16.31% | 5 | May 6, 2026 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $40 → $50 | $42.84 | +16.71% | 6 | May 6, 2026 | |
| BNTX BioNTech SE | Maintains: Overweight | $150 → $140 | $93.66 | +49.48% | 3 | May 6, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $150 → $145 | $112.37 | +29.04% | 15 | May 1, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $825 → $800 | $723.41 | +10.59% | 23 | Apr 30, 2026 | |
| BIIB Biogen | Upgrades: Overweight | $200 → $250 | $199.36 | +25.40% | 17 | Apr 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $70.93 | +5.74% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $336.29 | +11.51% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $52.88 | +41.83% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $155.80 | +12.32% | 8 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $165 | $134.94 | +22.28% | 14 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $60 | $56.45 | +6.29% | 11 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,200 → $1,280 | $989.87 | +29.31% | 19 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $4.09 | +22.25% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.90 | +321.05% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $448.29 | +14.88% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $29.26 | +87.97% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $207.86 | +25.08% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $55.00 | -14.55% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $18.95 | +58.31% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $36.70 | +90.74% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.87 | +15.96% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $24.29 | +7,619.23% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.62 | +443.81% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $8.17 | +132.56% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.50 | +3,900.00% | 4 | Dec 3, 2019 |
Jazz Pharmaceuticals
May 6, 2026
Maintains: Overweight
Price Target: $250 → $265
Current: $227.84
Upside: +16.31%
Travere Therapeutics
May 6, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $42.84
Upside: +16.71%
BioNTech SE
May 6, 2026
Maintains: Overweight
Price Target: $150 → $140
Current: $93.66
Upside: +49.48%
Merck & Co.
May 1, 2026
Maintains: Overweight
Price Target: $150 → $145
Current: $112.37
Upside: +29.04%
Regeneron Pharmaceuticals
Apr 30, 2026
Maintains: Equal-Weight
Price Target: $825 → $800
Current: $723.41
Upside: +10.59%
Biogen
Apr 20, 2026
Upgrades: Overweight
Price Target: $200 → $250
Current: $199.36
Upside: +25.40%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $70.93
Upside: +5.74%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $336.29
Upside: +11.51%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $52.88
Upside: +41.83%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $155.80
Upside: +12.32%
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $134.94
Upside: +22.28%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $56.45
Upside: +6.29%
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $989.87
Upside: +29.31%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $4.09
Upside: +22.25%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.90
Upside: +321.05%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $448.29
Upside: +14.88%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $29.26
Upside: +87.97%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $207.86
Upside: +25.08%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $55.00
Upside: -14.55%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $18.95
Upside: +58.31%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $36.70
Upside: +90.74%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.87
Upside: +15.96%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $24.29
Upside: +7,619.23%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $6.62
Upside: +443.81%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $8.17
Upside: +132.56%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.50
Upside: +3,900.00%